To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma

Clinical trial NCT06204991 · RECRUITING

Trial details

NCT number: NCT06204991
Sponsor: Inge Marie Svane
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Melanoma Stage III Melanoma Stage IV Melanoma

Start date: 2025-04-01
Primary completion: 2027-03-01
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.